Asuragen, Inc.

Mirna Therapeutics, Inc.

The Johns Hopkins University

Mima Therapeutics, Inc

Yale University

Kevin Kelnar

David Allen Brown

Mike Byrom

Dmitriy Ovcharenko

Eric Devroe

Lance Ford

Angie Cheng

Rich Jarvis

Jeffrey Shelton

Peter Anthony Campochiaro

Jikui Shen

Alex Adai

Andreas Bader

Stephanie Volz

Jason F Wiggins

Lubna Patrawala

Andreas G Bader

David Brown

Charles D Johnson

Embodiments concern methods and compositions involving miR-124 mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-124 sequence and a complementary passenger strand.

Synthetic mimics of miR-124

The present invention concerns methods and compositions for diagnosing and/or treating vascular diseases including cancer, cardiac diseases, vascular diseases of the eye, and inflammatory diseases. The methods involve measuring the levels of one or multiple miRNAs in patient samples and using the test results to diagnose and/or predict an optimal treatment regimen for the patient. Compositions described in the invention include nucleic acids that function as miRNAs or miRNA inhibitors that can be introduced to a patient to reduce or increase vascularization as needed.

Compositions and methods related to miRNA modulation of neovascularization or angiogenesis

The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

Methods and compositions involving miRNA and miRNA inhibitor molecules

Embodiments concern methods and compositions involving miR-34 mimics, including miR-34a and miR-34c mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34a sequence and a complementary passenger strand. In additional embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-34c sequence and a complementary passenger strand.

Synthetic mimics of miR-34

Synthetic mimics of MIR-124

This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer.

MiRNA biomarkers of prostate disease

Embodiments concern methods and compositions involving miR-mimics, including miR-and miR-mimics. In some embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-sequence and a complementary passenger strand. In additional embodiments, there are double-stranded RNA molecules with modified nucleotides having an active strand with a miR-sequence and a complementary passenger strand.

Growing community of inventors

Kyle, TX, United States of America

Kevin Kelnar